Clinical Trials Logo

Filter by:
NCT ID: NCT03706365 Active, not recruiting - Prostate Cancer Clinical Trials

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

CYCLONE 2
Start date: November 26, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

NCT ID: NCT03705403 Active, not recruiting - NSCLC Stage IV Clinical Trials

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

IMMUNOSABR2
Start date: April 4, 2019
Phase: Phase 2
Study type: Interventional

This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm. Patients with oligometastatic disease will receive SABR to minimal 1 and max all metastatic sites (max 5 sites irradiated) and patients with diffuse metastatic lesions (6 to max 10) will receive radiotherapy to max 5 sites. In the experimental arm, immunotherapy will be given after irradiation.

NCT ID: NCT03704415 Active, not recruiting - Asthma Clinical Trials

Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative)

Start date: October 23, 2018
Phase: N/A
Study type: Interventional

This randomized study compares operative techniques in chronic rhinosinusitis with polyposis (CRSwNP) surgery. It aims to evaluate outcomes in asthma and CRSwNP, safety and costs. The investigators want to see if patients with certain clinical and/or genetic predispositions will benefit from extended surgery. They also aim to find biomarkers for detection and management models for of severe airway inflammation and to further develop markers for progressive disease forms.

NCT ID: NCT03703297 Active, not recruiting - Clinical trials for Small Cell Lung Cancer

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

ADRIATIC
Start date: September 27, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT ID: NCT03699345 Active, not recruiting - Clinical trials for Aortic Valve Stenosis

CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System

Start date: January 7, 2019
Phase:
Study type: Observational

This study will monitor device performance and safety of the Edwards CENTERA Transcatheter Heart Valve (THV) system in patients with severe, symptomatic aortic valve stenosis who are indicated for aortic valve replacement.

NCT ID: NCT03697707 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia in Remission

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

ADVANCE-II
Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD

NCT ID: NCT03695484 Active, not recruiting - Atrial Fibrillation Clinical Trials

Registry Evaluating AF Ablation Techniques

PRIME-AF
Start date: October 31, 2018
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational registry is to prospectively collect procedure efficiency, safety and acute and long term outcome data from catheter ablation procedures as treatment of paroxysmal atrial fibrillation, using the following treatment modalities: - Cryoballoon ablation - Manual guided RF ablation using Contact Force catheters - Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings - Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings

NCT ID: NCT03692065 Active, not recruiting - Clinical trials for Cancer-associated Thrombosis

API-CAT STUDY for APIxaban Cancer Associated Thrombosis

API-CAT
Start date: October 11, 2018
Phase: Phase 3
Study type: Interventional

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of anticoagulant therapy for treating a documented index event of proximal deep venous thrombosis (DVT) (symptomatic or incidental) or pulmonary embolism (symptomatic or incidental).

NCT ID: NCT03690388 Active, not recruiting - Clinical trials for Differentiated Thyroid Cancer

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Start date: October 5, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

NCT ID: NCT03682536 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

COMMANDS
Start date: January 2, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).